8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 9, 2026·SEC
Voyager Therapeutics, Inc.(VYGR)Earnings, Financials & Key Ratios
VYGR•NASDAQ
Price updated Jun 19, 2026
AboutVoyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$40M-49.5%
- EBITDA-$128M-62.7%
- Net Income-$120M-84.2%
- EPS (Diluted)-2.04-80.5%
- Gross Margin100%
- EBITDA Margin-316.5%-222.3%
- Operating Margin-326.56%-213.7%
- Net Margin-296.53%-265.0%
- ROE-48.29%-99.1%
VYGR Key Insights
Voyager Therapeutics, Inc. (VYGR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 25.1% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VYGR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VYGR Price & Volume
Voyager Therapeutics, Inc. (VYGR) stock price & volume — 10-year historical chart
Loading chart...
VYGR Growth Metrics
Voyager Therapeutics, Inc. (VYGR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.82%
5 Years-25.09%
3 Years-0.44%
TTM-45.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-35.62%
Return on Capital
10 Years-22.59%
5 Years-18.14%
3 Years-2.48%
Last Year-46.34%
VYGR Recent Earnings
Voyager Therapeutics, Inc. (VYGR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.47+13.0%
$0.54
Rev
$3M-70.5%
$9M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.47+13.0%
$0.54
Rev
$3M-70.5%
$9M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.46+14.8%
$0.54
Rev
$15M+46.2%
$10M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.47+11.3%
$0.53
Rev
$13M+27.4%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.47vs $0.54+13.0% | $3Mvs $9M-70.5% |
| Q2 2026 | May 5, 2026 | $0.47vs $0.54+13.0% | $3Mvs $9M-70.5% |
| Q2 2026 | Mar 9, 2026 | $0.46vs $0.54+14.8% | $15Mvs $10M+46.2% |
| Q4 2025 | Nov 10, 2025 | $0.47vs $0.53+11.3% | $13Mvs $10M+27.4% |
Based on last 12 quarters of dataView full earnings history →
VYGR Peer Comparison
Voyager Therapeutics, Inc. (VYGR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 |
Compare VYGR vs Peers
Voyager Therapeutics, Inc. (VYGR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VYGR Income Statement
Voyager Therapeutics, Inc. (VYGR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 10.13M | 7.62M | 104.39M | 171.13M | 37.41M | 40.91M | 250.01M | 80M | 40.37M | 36.49M |
Revenue Growth % | -28.73% | -24.82% | 1270.14% | 63.93% | -78.14% | 9.33% | 511.16% | -68% | -49.53% | -45.5% |
Cost of Goods Sold | 62.26M | 64.91M | 119.73M | 108.75M | 73.79M | 55.76M | 92.17M | 0 | 0 | 932K |
COGS % of Revenue | 614.31% | 851.88% | 114.7% | 63.55% | 197.21% | 136.32% | 36.87% | - | - | - |
Gross Profit | -52.13M▲ 0% | -57.29M▼ 9.9% | -15.34M▲ 73.2% | 62.38M▲ 506.5% | -36.37M▼ 158.3% | -14.86M▲ 59.2% | 157.84M▲ 1162.4% | 80M▼ 49.3% | 40.37M▼ 49.5% | 35.56M▲ 0% |
Gross Margin % | -514.31% | -751.88% | -14.7% | 36.45% | -97.21% | -36.32% | 63.13% | 100% | 100% | 97.45% |
Gross Profit Growth % | -85.97% | -9.9% | 73.22% | 506.51% | -158.31% | 59.15% | 1162.37% | -49.31% | -49.53% | - |
Operating Expenses | 82M | 98.71M | 36.34M | 34.99M | 37.25M | 35.98M | 35.82M | 163.29M | 172.22M | 162.98M |
OpEx % of Revenue | 809.06% | 1295.63% | 34.81% | 20.45% | 99.55% | 87.96% | 14.33% | 204.11% | 426.56% | - |
Selling, General & Admin | 19.74M | 33.81M | 36.34M | 34.99M | 37.25M | 30.98M | 35.82M | 35.92M | 37.54M | 36.16M |
SG&A % of Revenue | 194.75% | 443.75% | 34.81% | 20.45% | 99.55% | 75.73% | 14.33% | 44.9% | 92.99% | - |
Research & Development | 62.26M | 64.91M | 119.73M | 108.75M | 73.79M | 60.76M | 92.17M | 127.37M | 134.67M | 127.75M |
R&D % of Revenue | 614.31% | 851.88% | 114.7% | 63.55% | 197.21% | 148.54% | 36.87% | 159.21% | 333.57% | - |
Other Operating Expenses | 1.17M | 2.63M | -119.73M | -108.75M | -73.79M | -55.76M | -92.17M | 0 | 0 | -932K |
Operating Income | -71.86M▲ 0% | -91.09M▼ 26.8% | -51.68M▲ 43.3% | 27.38M▲ 153.0% | -73.62M▼ 368.8% | -50.84M▲ 30.9% | 122.01M▲ 340.0% | -83.29M▼ 168.3% | -131.84M▼ 58.3% | -127.42M▲ 0% |
Operating Margin % | -709.06% | -1195.63% | -49.51% | 16% | -196.76% | -124.27% | 48.8% | -104.11% | -326.56% | -349.16% |
Operating Income Growth % | -74.01% | -26.76% | 43.27% | 152.99% | -368.84% | 30.94% | 340.01% | -168.26% | -58.3% | - |
EBITDA | -70.27M | -88.98M | -48.91M | 31.2M | -68.45M | -44.65M | 126.45M | -78.56M | -127.78M | -123.44M |
EBITDA Margin % | -693.32% | -1167.84% | -46.86% | 18.23% | -182.96% | -109.14% | 50.58% | -98.19% | -316.5% | -338.26% |
EBITDA Growth % | -72.7% | -26.63% | 45.03% | 163.79% | -319.39% | 34.78% | 383.24% | -162.12% | -62.67% | -26.94% |
D&A (Non-Cash Add-back) | 1.59M | 2.12M | 2.77M | 3.82M | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M | 3.98M |
EBIT | -71.86M | -91.09M | -51.68M | 27.38M | -73.62M | -45.84M | 122.01M | -83.29M | -131.84M | -124.64M |
Net Interest Income | 1.23M | 3.31M | 6.46M | 1.66M | 0 | 1.79M | 11.72M | 18.33M | 10.62M | 9.24M |
Interest Income | 1.23M | 3.31M | 6.46M | 1.66M | 0 | 1.79M | 11.72M | 18.33M | 10.62M | 9.24M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.17M | 2.63M | 8.08M | 9.36M | 2.42M | 4.45M | 11.72M | 18.95M | 12.27M | 10.9M |
Pretax Income | -70.7M▲ 0% | -88.47M▼ 25.1% | -43.6M▲ 50.7% | 36.74M▲ 184.3% | -71.2M▼ 293.8% | -46.39M▲ 34.8% | 133.74M▲ 388.3% | -64.34M▼ 148.1% | -119.58M▼ 85.9% | -116.52M▲ 0% |
Pretax Margin % | -697.56% | -1161.15% | -41.76% | 21.47% | -190.29% | -113.41% | 53.49% | -80.42% | -296.17% | -319.27% |
Income Tax | 0 | -180K | 0 | 0 | 0 | 16K | 1.41M | 665K | 144K | 121K |
Effective Tax Rate % | 0% | 0.2% | 0% | 0% | 0% | -0.03% | 1.05% | -1.03% | -0.12% | -0.1% |
Net Income | -70.7M▲ 0% | -88.29M▼ 24.9% | -43.6M▲ 50.6% | 36.74M▲ 184.3% | -71.2M▼ 293.8% | -46.41M▲ 34.8% | 132.33M▲ 385.1% | -65M▼ 149.1% | -119.72M▼ 84.2% | -116.64M▲ 0% |
Net Margin % | -697.56% | -1158.79% | -41.76% | 21.47% | -190.29% | -113.45% | 52.93% | -81.25% | -296.53% | -319.61% |
Net Income Growth % | -75.9% | -24.88% | 50.62% | 184.27% | -293.78% | 34.82% | 385.14% | -149.12% | -84.18% | -37.72% |
Net Income (Continuing) | -70.7M | -88.29M | -43.6M | 36.74M | -71.2M | -46.41M | 132.33M | -65M | -119.72M | -116.64M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.64▲ 0% | -2.75▼ 4.2% | -1.14▲ 58.5% | 0.98▲ 186.0% | -1.75▼ 278.6% | -1.21▲ 30.9% | 2.97▲ 345.5% | -1.13▼ 138.0% | -2.04▼ 80.5% | -1.96▲ 0% |
EPS Growth % | -66.04% | -4.17% | 58.55% | 185.96% | -278.57% | 30.86% | 345.45% | -138.05% | -80.53% | -35.62% |
EPS (Basic) | -2.64 | -2.75 | -1.14 | 0.99 | -1.75 | -1.21 | 3.08 | -1.13 | -2.04 | - |
Diluted Shares Outstanding | 26.8M | 32.07M | 35.9M | 37.35M | 37.67M | 38.36M | 44.57M | 57.67M | 58.69M | 59.5M |
Basic Shares Outstanding | 26.8M | 32.07M | 35.9M | 37.13M | 37.67M | 38.36M | 43.02M | 57.67M | 58.69M | 59.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VYGR Balance Sheet
Voyager Therapeutics, Inc. (VYGR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 171.79M | 162.48M | 304.66M | 197.77M | 136.7M | 124.5M | 319.68M | 276.81M | 202.69M | 146.98M |
Cash & Short-Term Investments | 169.05M | 155.81M | 281.53M | 181.14M | 132.54M | 118.85M | 230.88M | 266.68M | 196.45M | 141.48M |
Cash Only | 31.53M | 46.86M | 86.04M | 104.44M | 117.43M | 98.96M | 68.8M | 71.37M | 65.3M | 43.31M |
Short-Term Investments | 137.52M | 108.95M | 195.49M | 76.7M | 15.11M | 19.89M | 162.07M | 195.32M | 131.15M | 98.17M |
Accounts Receivable | 0 | 201K | 18.7M | 8.01M | 748K | 639K | 84.45M | 4.49M | 1.76M | 1.65M |
Days Sales Outstanding | - | 9.63 | 65.38 | 17.09 | 7.3 | 5.7 | 123.3 | 20.49 | 15.92 | 24.92 |
Inventory | 1.85M | 5.11M | 2.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 10.85 | 28.76 | 6.71 | - | - | - | - | - | - | - |
Other Current Assets | 2.22M | 1.36M | 1.95M | 7.16M | 1.7M | 4.23M | 2.63M | 2.87M | 4.48M | 3.86M |
Total Non-Current Assets | 12.69M | 14.55M | 50.1M | 63.81M | 57.16M | 34.86M | 31.6M | 116.24M | 49.59M | 72.34M |
Property, Plant & Equipment | 10.28M | 12.77M | 46.46M | 61.5M | 55.38M | 33.34M | 30M | 47.66M | 41.61M | 39.43M |
Fixed Asset Turnover | 0.99x | 0.60x | 2.25x | 2.78x | 0.68x | 1.23x | 8.33x | 1.68x | 0.97x | 0.86x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.1M | 628K | 1.92M | 0 | 0 | 0 | 0 | 65.7M | 0 | 66.53M |
Other Non-Current Assets | 1.3M | 1.15M | 1.72M | 2.32M | 1.78M | 1.51M | 1.59M | 2.87M | 7.98M | 32.92M |
Total Assets | 184.48M▲ 0% | 177.03M▼ 4.0% | 354.76M▲ 100.4% | 261.58M▼ 26.3% | 193.85M▼ 25.9% | 159.36M▼ 17.8% | 351.28M▲ 120.4% | 393.05M▲ 11.9% | 252.28M▼ 35.8% | 219.32M▲ 0% |
Asset Turnover | 0.05x | 0.04x | 0.29x | 0.65x | 0.19x | 0.26x | 0.71x | 0.20x | 0.16x | 0.13x |
Asset Growth % | -2.68% | -4.04% | 100.4% | -26.26% | -25.89% | -17.8% | 120.44% | 11.89% | -35.81% | -132.21% |
Total Current Liabilities | 15.9M | 31.67M | 76.01M | 26.77M | 50.98M | 72.59M | 64.51M | 49.79M | 26.54M | 17.45M |
Accounts Payable | 1.02M | 1.04M | 4.07M | 634K | 574K | 2.57M | 1.6M | 4M | 5.01M | 2.72M |
Days Payables Outstanding | 5.98 | 5.84 | 12.41 | 2.13 | 2.84 | 16.8 | 6.35 | - | - | 1.14K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.84M | 0 |
Deferred Revenue (Current) | 3.38M | 20.85M | 47.23M | 0 | 33.89M | 59.38M | 42.88M | 24.39M | 1.59M | 1.99M |
Other Current Liabilities | 8.11M | 6.01M | 15.78M | 7.73M | 5.02M | 4.56M | 6.61M | 6.75M | 12.1M | 6.97M |
Current Ratio | 10.81x | 5.13x | 4.01x | 7.39x | 2.68x | 1.72x | 4.96x | 5.56x | 7.64x | 8.42x |
Quick Ratio | 10.69x | 4.97x | 3.98x | 7.39x | 2.68x | 1.72x | 4.96x | 5.56x | 7.64x | 8.42x |
Cash Conversion Cycle | - | 32.55 | 59.69 | - | - | - | - | - | - | -1.12K |
Total Non-Current Liabilities | 34.53M | 98.91M | 179.24M | 80.5M | 47.82M | 27.75M | 50.45M | 43.5M | 29.66M | 28.2M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 30.98M | 43.41M | 38.61M | 20.29M | 17.09M | 36.5M | 28.66M | 118.95M |
Deferred Tax Liabilities | 0 | 0 | -47.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6.35M | 6.71M | 1M | 37.09M | 1M | 1M | 1M | 1M | 1M | 1M |
Total Liabilities | 50.43M | 130.58M | 255.25M | 107.26M | 98.8M | 100.34M | 114.96M | 93.29M | 56.2M | 45.66M |
Total Debt | 0 | 0 | 34.17M | 47.61M | 44.18M | 23.13M | 20.29M | 43.73M | 36.5M | 34.57M |
Net Debt | -31.53M | -46.86M | -51.87M | -56.83M | -73.25M | -75.83M | -48.51M | -27.64M | -28.8M | -8.75M |
Debt / Equity | - | - | 0.34x | 0.31x | 0.46x | 0.39x | 0.09x | 0.15x | 0.19x | 0.20x |
Debt / EBITDA | - | - | - | 1.53x | - | - | 0.16x | - | - | -0.28x |
Net Debt / EBITDA | - | - | - | -1.82x | - | - | -0.38x | - | - | 0.07x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 134.05M▲ 0% | 46.45M▼ 65.4% | 99.51M▲ 114.3% | 154.32M▲ 55.1% | 95.06M▼ 38.4% | 59.02M▼ 37.9% | 236.32M▲ 300.4% | 299.76M▲ 26.8% | 196.08M▼ 34.6% | 173.67M▲ 0% |
Equity Growth % | -1.38% | -65.35% | 114.25% | 55.08% | -38.4% | -37.91% | 300.41% | 26.85% | -34.59% | -131.62% |
Book Value per Share | 5.00 | 1.45 | 2.77 | 4.13 | 2.52 | 1.54 | 5.30 | 5.20 | 3.34 | 2.92 |
Total Shareholders' Equity | 134.05M | 46.45M | 99.51M | 154.32M | 95.06M | 59.02M | 236.32M | 299.76M | 196.08M | 173.67M |
Common Stock | 32K | 32K | 37K | 37K | 38K | 38K | 44K | 55K | 59K | 60K |
Retained Earnings | -160.71M | -269.05M | -312.65M | -275.91M | -347.1M | -393.51M | -261.18M | -326.18M | -445.9M | -473.84M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -287K | -133K | -104K | -134K | -138K | -219K | -48K | -407K | 32K | -263K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VYGR Cash Flow Statement
Voyager Therapeutics, Inc. (VYGR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -61.35M | -15.89M | 48.67M | -96.72M | -53.52M | -12.51M | 77.92M | -15.31M | -132.47M | -127.99M |
Operating CF Margin % | -605.33% | -208.52% | 46.62% | -56.52% | -143.06% | -30.58% | 31.17% | -19.14% | -328.1% | - |
Operating CF Growth % | -44.41% | 74.1% | 406.33% | -298.73% | 44.66% | 76.63% | 722.9% | -119.65% | -765.23% | -112.82% |
Net Income | -70.7M | -88.29M | -43.6M | 36.74M | -71.2M | -46.41M | 132.33M | -65M | -119.72M | -116.64M |
Depreciation & Amortization | 1.59M | 2.12M | 2.77M | 3.82M | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M | 3.61M |
Stock-Based Compensation | 9.24M | 15.71M | 15.64M | 14.93M | 11.32M | 9.34M | 11.15M | 14.79M | 14.79M | 13.6M |
Deferred Taxes | -24K | -2.16M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 674K | 1.36M | -4.58M | -7.67M | -2.11M | -2.11M | -3.45M | -4.68M | -2.83M | -1.82M |
Working Capital Changes | -2.13M | 55.38M | 78.44M | -144.54M | 3.29M | 20.47M | -66.56M | 34.86M | -28.76M | -26.75M |
Change in Receivables | 0 | 0 | -18.5M | 10.48M | 7.28M | 475K | -83.23M | 81.31M | 268K | 465K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 470K | -282K | 2.6M | -3.44M | -60K | 1.99M | -962K | 2.39M | 1.02M | 89K |
Cash from Investing | -3.68M | 26.47M | -90.48M | 113M | 65.91M | -7.34M | -141.64M | -94.86M | 125.45M | 92.35M |
Capital Expenditures | -3.98M | -4.3M | -7.72M | -12.1M | -1.61M | -2.49M | -3.26M | -3.52M | -2.6M | -1.95M |
CapEx % of Revenue | 39.32% | 56.5% | 7.39% | 7.07% | 4.3% | 6.09% | 1.3% | 4.4% | 6.43% | 5.35% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 138.39M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 304K | 30.77M | 172K | 0 | 0 | 0 | -138.39M | 0 | 0 | 0 |
Cash from Financing | 59.92M | 4.75M | 80.99M | 3.16M | 612K | 1.11M | 33.65M | 114.02M | 816K | 4.07M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 57.99M | 0 | 77.62M | 0 | 612K | 1.11M | 33.65M | 114.02M | 816K | 4.07M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 860K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.93M | 4.75M | 3.38M | 3.16M | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | -5.11M▲ 0% | 15.33M▲ 399.9% | 39.18M▲ 155.6% | 18.4M▼ 53.0% | 12.99M▼ 29.4% | -18.47M▼ 242.2% | -30.08M▼ 62.8% | 3.85M▲ 112.8% | -6.21M▼ 261.3% | -34.32M▲ 0% |
Free Cash Flow | -65.33M▲ 0% | -20.19M▲ 69.1% | 40.95M▲ 302.8% | -108.81M▼ 365.7% | -55.13M▲ 49.3% | -15M▲ 72.8% | 74.66M▲ 597.8% | -18.83M▼ 125.2% | -135.06M▼ 617.2% | -129.94M▲ 0% |
FCF Margin % | -644.65% | -265.02% | 39.23% | -63.59% | -147.36% | -36.67% | 29.86% | -23.54% | -334.53% | -356.07% |
FCF Growth % | -37.52% | 69.09% | 302.79% | -365.73% | 49.33% | 72.79% | 597.75% | -125.22% | -617.24% | -13.98% |
FCF per Share | -2.44 | -0.63 | 1.14 | -2.91 | -1.46 | -0.39 | 1.68 | -0.33 | -2.30 | -2.18 |
FCF Conversion (FCF/Net Income) | 0.87x | 0.18x | -1.12x | -2.63x | 0.75x | 0.27x | 0.59x | 0.24x | 1.11x | 1.11x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VYGR Key Ratios
Voyager Therapeutics, Inc. (VYGR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -52.37% | -97.83% | -59.74% | 28.95% | -57.1% | -60.24% | 89.61% | -24.25% | -48.29% | -55.97% |
Return on Invested Capital (ROIC) | -53.42% | -133.82% | -164.15% | 28.3% | -92.57% | -1528.78% | 107.03% | -27.16% | -45.01% | -48.67% |
Gross Margin | -514.31% | -751.88% | -14.7% | 36.45% | -97.21% | -36.32% | 63.13% | 100% | 100% | 97.45% |
Net Margin | -697.56% | -1158.79% | -41.76% | 21.47% | -190.29% | -113.45% | 52.93% | -81.25% | -296.53% | -319.61% |
Debt / Equity | - | - | 0.34x | 0.31x | 0.46x | 0.39x | 0.09x | 0.15x | 0.19x | 0.20x |
FCF Conversion | 0.87x | 0.18x | -1.12x | -2.63x | 0.75x | 0.27x | 0.59x | 0.24x | 1.11x | 1.11x |
Revenue Growth | -28.73% | -24.82% | 1270.14% | 63.93% | -78.14% | 9.33% | 511.16% | -68% | -49.53% | -45.5% |
Related:VYGR Dividend History·VYGR Revenue History·VYGR Price History·VYGR P/E History·VYGR Financial Ratios·VYGR Institutional Holders
VYGR SEC Filings & Documents
Voyager Therapeutics, Inc. (VYGR) SEC filings — annual & quarterly reports (10-K, 10-Q)
VYGR Frequently Asked Questions
Voyager Therapeutics, Inc. (VYGR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Voyager Therapeutics, Inc. (VYGR) reported $36.5M in revenue for fiscal year 2025.
Voyager Therapeutics, Inc. (VYGR) saw revenue decline by 49.5% over the past year.
Voyager Therapeutics, Inc. (VYGR) reported a net loss of $116.6M for fiscal year 2025.
Dividend & Returns
Voyager Therapeutics, Inc. (VYGR) has a return on equity (ROE) of -48.3%. Negative ROE indicates the company is unprofitable.
Voyager Therapeutics, Inc. (VYGR) had negative free cash flow of $129.9M in fiscal year 2025, likely due to heavy capital investments.